The announcement was made during an official ceremony attended by the Ambassador of Sweden to Egypt, Mr. Dag Juhlin-Dannfelt with a distinguished group of leading professors, experts, and heads of scientific societies specializing in pediatrics, hematology, rheumatology, and kidney transplantation, reflecting the growing interest in rare diseases and the role of precision medicine in improving patient outcomes.
Dr. Ahmed Abou Dahab, Vice President for the Middle East, North Africa, and Turkey at Sobi, emphasized that this agreement marks an important step toward establishing a comprehensive framework for pharmaceutical collaboration in Egypt. He noted that the partnership aims to address critical therapeutic gaps in rare diseases by providing access to the latest high-quality innovative medicines, aligned with the most up-to-date global treatment guidelines.
He affirmed the company’s commitment to supporting Egyptian patients, highlighting that Egypt represents a strategic hub for the Middle East region due to its strong healthcare infrastructure, the high expertise of its medical teams, the country’s expansion in offering advanced treatments, and the national direction toward building a more sustainable and resilient healthcare system.
He also explained that Sobi operates with a long-term vision to strengthen cooperation with Egyptian institutions to support patients suffering from rare and complex conditions that require precise and fully integrated therapeutic solutions.
In his remarks, Dr. Karim El-Ashram, Chief Operating Officer ,expressed his pleasure with this partnership, which reflects the mutual trust between both parties. He pointed out that Soficopharm’s long-standing experience in the Egyptian market is a key pillar for the success of this collaboration.
He stressed his strong belief that this agreement will contribute to building a solid partnership with the medical community and enhancing patients’ access to world-class treatments. He added that it also comes as an extension of the company’s strategy to support the pharmaceutical sector in Egypt, promote reliance on modern therapeutic solutions, and help ensure the availability of essential medical needs.
Rare diseases are among the health areas that require special attention, with more than 300 million people worldwide suffering from one or more of these conditions, which are often chronic, complex, and dependent on specialized treatments that are not readily accessible.
In Egypt, health authorities and pharmaceutical companies continue working to expand access and introduce innovative solutions, especially in light of the significant progress the healthcare sector has witnessed in recent years.
Short link: